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Abstract: Caspase-2 activation by formation of PIDDosome is critical for genotoxic stress 
induced apoptosis. PIDDosome is composed of three proteins, RAIDD, PIDD, and 
Caspase-2. RAIDD is an adaptor protein containing an N-terminal Caspase-Recruiting-
Domain (CARD) and a C-terminal Death-Domain (DD). Its interactions with Caspase-2 
and PIDD through CARD and DD respectively and formation of PIDDosome are important 
for the activation of Caspase-2. RAIDD DD cloned into pET26b vector was expressed in 
E. coli cells and purified by nickel affinity chromatography and gel filtration. Although it 
has been known that the most DDs are not soluble in physiological condition, RAIDD DD 
was soluble and interacts tightly with PIDD DD in physiological condition. The purified 
RAIDD DD alone has been crystallized. Crystals are trigonal and belong to space group 
P3121 (or its enantiomorph P3221) with unit-cell parameters a = 56.3, b = 56.3, c = 64.9 Å 
and  γ =  120°. The crystals were obtained at room temperature and diffracted to   
2.0 Å resolution.  
 









1. Introduction  
 
Death-Domains (DDs) are protein interaction modules composed of six-helix bundle. DDs, together 
with DEDs, CARDs, and PYDs, comprise the DD superfamily and has a pivotal role in apoptosis 
signaling pathway by mediating homotypic interaction [1,2]. Apoptosis signaling pathway is mediated 
by sequential activation of caspases that is cysteinyl protease. Activation of caspases is mediated by 
large molecular complexes in the apoptosis signaling pathway [3,4,5,6]. 
PIDDosome, caspase-2 activating large molecular complex, is composed of three different protein 
components including PIDD (p53-induced protein with a DD), RAIDD (RIP-associated ICH-1 
homologous protein with a death domain), and caspase-2 [5]. Caspase-2 activation by PIDDosome is 
critical for genotoxic stress induced apoptosis [7]. PIDD contains 910 residues with seven leucine rich 
repeats (LRRs), two ZU-5 domains and a C-terminal Death Domain (DD) [8]. PIDD is essential for 
cell death, which it facilitates by activating caspase-2. In addition, PIDD is also critical for cell 
survival due to its interaction with RIP1, a kinase that has been implicated in the activation of NF-κB 
[7]. The results of several studies indicate that PIDD may be a molecular switch that controls the 
balance between life and death upon genotoxic stress [7]. Caspase-2 is the second caspase to be 
identified and is the most evolutionarily conserved caspase cross the species of animal [9]. RAIDD, an 
adaptor protein containing both an N-terminal CARD and a C-terminal DD, interacts to Caspase-2 and 
PIDD through CARD-CARD and DD-DD respectively [10,11]. Despite the fundamental importance of 
the Death-Domain superfamily in apoptotic and inflammatory signaling pathways, limited crystal 
structures are available [12].  
As the first step toward elucidating molecular structure of PIDDosome and further understanding 
homotypic interaction of DD in apoptosis signaling pathway, we over-expressed, purified and 
crystallized RAIDD DD. Although it has been known that most DDs are not soluble under 
physiological conditions [13,14], RAIDD DD was soluble and interacts tightly with PIDD DD under 
physiological conditions. Crystals are trigonal and belong to space group P3121 with unit-cell 
parameters a = 56.3, b = 56.3, c = 64.9 Å and γ= 120°. The crystals were obtained at room temperature 
and diffracted to 2.0 Å resolution. Details of the structure of RAIDD DD should enable us to 
understand the mechanism of the PIDDosome formation via DD:DD interaction.  
 
2. Results and Discussion 
 
 2.1. Over-expression and purification of RAIDD DD 
 
As described below in the Experimental section, a DNA fragment encoding the RAIDD DD (94-
199) was cloned by the polymerase chain reaction (PCR) using a plasmid DNA containing the full-
length RAIDD gene as the template in order to elucidate the molecular structure of RAIDD DD by the 
X-ray protein crystallography. Ligation of the PCR product to the expression vector pET-26b produces 
plasmid pET26RAIDD-DD. This vector construction adds an eight-residue tag including C-terminal 
hexahistidine which has been used as efficient tag for affinity chromatography. The resulting plasmid 
was transformed into BL21 (DE3) E. coli competent cells and expressed by treating the bacteria with 




by gel-filtration chromatography, we could obtain pure RAIDD DD protein (Figure 1). The main peak 
that contains RAIDD DD eluted around 10 kDa position. It indicates RAIDD DD is existed as a 
monomer in solution. 
 
Figure 1. Purification of the RAIDD DD. The profile showing the elution of the RAIDD 


















RAIDD DD was concentrated to 4-6 mg mL
-1 using an Millipore concentration kit (Millipore) for 
crystallization trials. The selenomethionine-substituted RAIDD DD was expressed in the methionine 
auxotrophic strain B834 (Novagen) grown in minimal medium supplemented with seleno-L-
methionine (Sigma) and other nutrients. It was purified and crystallized using the same procedure as 
used for the native protein. 
 
2.2. Crystallization of RAIDD DD 
 
Crystallization conditions were initially screened at 297K by the hanging-drop vapor-diffusion 
method using screening kits from Hampton Research (Crystal screening I and II, Natrix, MembFac, 
SaltRX) and from deCODE Biostructures Group (Wizard I and II). Crystals were grown on a 
siliconized cover slip by equilibrating a mixture containing 1 μL of protein solution (4-6 mg·mL
-1 
protein in 20 mM Tris-HCl at pH 8.0, 150 mM NaCl) and 1 μL of a reservoir solution (2 M Na/K 
phosphate at pH 7.0) against 0.5 ml of reservoir solution. Crystals appeared in three days and grew to a 
maximum dimension of 0.2 x 0.2 x 0.2 mm (Figure 2). The selenomethionine-substituted RAIDD DD 
crystals were also grown under the similar condition (2.1 M Na/K phosphate at pH 7.0). 
 




Figure 2. Crystal of RAIDD DD. A native RAIDD DD crystal grown in three days   
in the condition of 2 M Na/K phosphate at pH 7.0. Its approximate dimentions are 0.2 X 
















2.3. Preliminary X-ray diffraction studies 
 
For diffraction experiments, crystals were transiently soaked in a solution corresponding to the 
reservoir solution but supplemented with 20% (v/v) glycerol. The crystals were cryocooled at 110K. A 
single-wavelength anomalous diffraction (SAD) data set was collected at the selenium peak 
wavelength (E=12664ev, λ=0.979Å) at the X4A beamline of National Synchrotron Light Source 
(NSLS). Selenium labeled methionine will be found and the structure will be phased using the program 
SOLVE/RESOLVE [15]. Data processing and scaling was carried out in the HKL2000 package [16]. 
A native data set was collected and used for model refinement using CNS [17]. The data-collection 
statistics are summarized in Table 1. The structure was determined and deposited at protein data bank 
(PDBID: 2O71) [19]. 
 
Table 1. Crystallographic statistics. 
Data collection  Se-Met  Native 
Space group  P3121 P3121 
Cell dimensions     
a, b, c  56.3Å, 56.3Å, 64.9Å  56.1Å, 56.1Å, 64.9Å 
Resolution 50-2.0Å  50-2.0Å 
†Rsym   6.2% (27.4%)  5.5% (17.9%) 
†I/σ(I)  17.2 (2.8)  14.5 (2.3) 
†Completeness   100.0% (100.0%)  99.7% (99.8%) 
†Redundancy  11.0 (10.6)  8.9 (8.9) 




Table 1. Cont. 
Refinement   
Resolution   50-2.0Å 
No. reflections used 
(completeness) 
 8063  (96.9%) 
Rwork/Rfree   23.1%/24.1% 
No. atoms     
Protein   704 
Water and other small molecule    55 
Average B-factors    
Protein   32.0  Å
2 
Water and other small molecule    40.4 Å
2 
R.m.s deviations     
Bond lengths    0.005Å 
Bond angles     1.0° 
Ramachandran Plot  
Most favored regions 





†Highest resolution shell is shown in parenthesis. 
 
2.4. Functional test of RAIDD DD 
 
DDs mediate protein-protein interaction. RAIDD DD is protein interaction module that is involved 
in the interaction to PIDD DD to form a PIDDosome. This homotypic interaction is critical for 
caspase-2 activation and genotoxic stress induced apoptosis. To test the function of purified RAIDD 
DD, we purified PIDD DD and analyzed binding ability of RAIDD DD to PIDD DD. Gel-filtration 
profile and SDS-PAGE clearly showed that RAIDD forms a tight complex with PIDD DD (Figure 3A, 
3B). The absolute molecular mass of 103 kDa (Figure 3C), determined by analytical equilibrium 
ultracentrifugation, indicates that the stoichiometry of the RAIDD DD: PIDD DD complex is 4:4 or 5:5. 
 
3. Experimental Section  
 
3.1. Expression and purification 
 
The construct for expression of human RAIDD DD (94-199) was made as follows. The cDNA of 
full length RAIDD DD was used as a template for the polymerase chain reaction (PCR) and the 
plasmid vector pET26b (Novagen, USA) was used to add a hexahistidine tag at the carboxy-terminus 
of RAIDD DD for affinity purification. PCR products were digested with NdeI  and  XhoI (New 
England Biolabs, USA) restriction enzymes and ligated into pET26b. This vector construction adds an 
eight-residue tag including C-terminal hexahistidine (LEHHHHHH). 




Figure 3. Functional test of RAIDD DD.  A. Profile of Gel-filtration chromatography. 
Elution volume around 12 mL indicates molecular weight of 120 kDa; B. 15 % SDS-
PAGE showed that the peak from profile of gel-filtration chromatography is a complex. 
Fraction #12 and #14 showed that uncomplexed left over proteins; C. The equilibrium 
radial absorbance profiles at 25,000 rev./min by analytical ultracentrifugation analysis for 
RAIDD DD: PIDD DD complex. 
 
 
The resulting plasmid was transformed into BL21 (DE3) E. coli competent cells. The expression 
was induced by treating the bacteria with 0.5 mM isopropyl β-D-thiogalactopyranoside (IPTG) for 
overnight at 293 K. The bacteria were then collected, resuspended and lysed by sonication in 50 mL 
lysis buffer (20 mM Tris-HCl at pH 7.9, 500 mM NaCl, 5 mM imidazole). The bacterial lysate was 
then centrifuged at 14,000 g for 1 hr at 277 K. The supernatant fraction was applied to gravity-flow 
column (Bio-Rad, USA) packed with Ni-NTA affinity resin (Qiagen, USA). The unbound bacterial 
proteins were removed from the column using washing buffer (20 mM Tris-HCl at pH 7.9, 500 mM 
NaCl, 60 mM imidazole and 10% glycerol). The C-terminal His6-tagged RAIDD DD was eluted from 
the column using an elution buffer (20 mM Tris-HCl at pH 8.0, 500 mM NaCl, 250 mM imidazole). 
The protein purity was further improved by using a Superdex 200 gel filtration column 10/30 
(Pharmacia) which was pre-equilibrated with a solution of 20 mM Tris-HCl at pH 8.0 and 150 mM KCl.  
RAIDD DD was concentrated to 4-6 mg mL
-1 using a Millipore concentration kit (Millipore, USA) 




methionine auxotrophic strain B834 (Novagen, USA) grown in minimal medium supplemented with 
seleno-L-methionine (Sigma, USA) and other nutrients. It was purified and crystallized using the same 




Crystallization conditions were initially screened at 297 K by the hanging-drop vapor-diffusion 
method using screening kits from Hampton Research (Crystal screening I and II, Natrix, MembFac, 
SaltRX) and from deCODE Biostructures Group (Wizard I and II). Crystals were grown on a 
siliconized cover slip by equilibrating a mixture containing 1 μL of protein solution (4-6 mg mL
-1 
protein in 20 mM Tris-HCl at pH 8.0, 150 mM NaCl) and 1 μL of a reservoir solution (2M Na/K 
phosphate at pH 7.0) against 0.5 mL of reservoir solution. Crystals appeared in three days and grew to 
a maximum dimension of 0.2 x 0.2 x 0.2 mm (Figure 1). The selenomethionine-substituted RAIDD 
DD crystals were also grown under the similar condition (2.1 M Na/K phosphate at pH 7.0). 
 
3.3. Data collection and analysis 
 
For diffraction experiments, crystals were transiently soaked in a solution corresponding to the 
reservoir solution but supplemented with 20% (v/v) glycerol. The crystals were cryocooled at 110 K 
using a nitrogen stream (Cryocool, Cryo Industries, New Hampshire, USA). A single-wavelength 
anomalous diffraction (SAD) data set was collected at the selenium peak wavelength (E=12664ev, 
λ=0.979Å) at the X4A beamline of National Synchrotron Light Source (NSLS). Data processing and 
scaling was carried out in the HKL2000 package [16]. A native data set was collected and used for 
model refinement. The data-collection statistics are summarized in Table 1. 
 
3.4. Gel filtration chromatography 
 
Purification method for PIDD DD is described at Park et al. [18]. Separately purified and quantified 
RAIDD DD, PIDD DD were incubated for 1hr at room temperature. Following pre-incubation, the 
mixture was concentrated to 15 ~ 20 mg mL
-1 using a concentration kit (Millipore, USA). The 
concentrated protein mixture was then applied to a Superdex 200 gel-filtration column 10/30 (GE 
healthcare, USA), which was pre-equilibrated with a solution of 20 mM Tris-HCl at pH 8.0 and   
50 mM NaCl. Formation of the complex was then detected by evaluating the positions of the eluted 




Analytical ultracentrifugation experiments were performed using a Beckman XL-1 analytical 
ultracentrifuge at 298 K. Absorbance was measured at the maximum wavelength as a function of 
radius at 25,000 rev./min. 
 




4. Conclusions  
 
In the current study, the RAIDD DD (94-199) of human RAIDD was over-expressed and purified. 
The recombinant RAIDD DD was fully functional by tight binding to PIDD DD which is well known 
binding partner. The purified RAIDD DD alone has been crystallized. Crystals are trigonal and belong 
to space group P3121 with unit-cell parameters a = 56.32, b = 56.32, c = 64.95 Å and γ = 120°. The 
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